ABILEAP
Live / Applied — First extension granted (statement of use) (as of 25 Feb 2026)
What this means for you
Not registered yet, but its 19 Jul 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98657918
- Mark type
- Stylized text
- Filed
- 19 Jul 2024
- Published for opposition
- 01 Jul 2025
- Attorney of record
- Max Vern
Goods and services
- Class 001 — Chemicals: Antibody products and molecules, namely, antibody reagents used for the detection of antigens in cells and tissue for scientific purposes; antibody products and molecules, namely, antibodies acting as immune modulators for scientific purposes
- Class 005 — Pharmaceuticals: Antibody products and molecules, namely, antibodies acting as immune modulators for medical purposes; colostral antibodies for medical purposes; pharmaceutical antibodies for medical use in the treatment of hereditary angioedema (HAE); pharmaceutical antibodies for medical use in the treatment of respiratory diseases and respiratory syndromes; pharmaceutical antibody preparations for the treatment of auto-immune diseases; pharmaceutical antibody preparations for the prevention and treatment of auto-immune diseases; pharmaceutical antibody preparations for the treatment of cancer; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; antibody products, namely, antibody reagents used for the detection of antigens in cells and tissue, for medical purposes
- Class 042 — Scientific and technological services: Antibody profiling for scientific research purposes and for discovery and development of new biotherapeutics; providing an online scientific database and website featuring information about medical and scientific research in the fields of cancer, immunology, inflammation, biologics, antibodies and molecules; molecule development, namely, pharmaceutical drug development services; scientific research in the field of conducting clinical trials for others; providing temporary use of a non-downloadable software for managing information in the fields of cancer, immunology, inflammation, biologics, antibodies and molecules; Platform as a service (PAAS) featuring a computer software platform for analyzing molecular and clinical data to develop antibodies against immune targets; chemical analysis in the field of molecular biology; biotherapeutic research services, namely, molecular analysis and product optimization for the purpose of pharmaceutical development
Owner
- ABILITY BIOLOGICS INC, Montreal, Quebec, CA
- ABILITY BIOLOGICS INC, Montreal, Quebec, CA
Prosecution history
- 26 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Feb 2026 — SOU EXTENSION 1 GRANTED
- 25 Feb 2026 — SOU EXTENSION 1 FILED
- 25 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 26 Aug 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 01 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Jul 2025 — PUBLISHED FOR OPPOSITION
- 25 Jun 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 29 May 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 29 May 2025 — EXAMINER'S AMENDMENT ENTERED
- 29 May 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 29 May 2025 — EXAMINERS AMENDMENT E-MAILED
- 29 May 2025 — EXAMINERS AMENDMENT -WRITTEN
- 02 May 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 02 May 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE